Plain-English translation of NCT06298916 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new imaging agent called 64Cu-LNTH-1363S, which is a radioactive substance used with a PET/CT scan to help doctors see certain types of cancers more clearly. The study has two parts: one to figure out the best dose and timing for the scan, and another to see how well the medication shows cancer cells that will be removed during planned surgery.
Current imaging methods don't always show all the cancer cells doctors need to see before surgery. This medication may help doctors get a better picture of where cancers are located so they can plan surgery more effectively.
You likely qualify if…
You likely don't qualify if…
If you join Part 1, you'll visit the clinic for screening, receive a single injection of the imaging agent, have PET/CT scans taken, and return for a safety check about a week later—the whole process takes about 3 weeks. If you join Part 2, you'll go through similar screening and imaging steps, but you'll also have your tumor tissue tested after your planned surgery to see how well the medication predicted what doctors found—this part takes about 10 to 11 weeks total.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States